219 related articles for article (PubMed ID: 22921944)
1. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity.
Misiak B; Leszek J; Kiejna A
Brain Res Bull; 2012 Nov; 89(3-4):144-9. PubMed ID: 22921944
[TBL] [Abstract][Full Text] [Related]
2. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.
Frisardi V; Solfrizzi V; Seripa D; Capurso C; Santamato A; Sancarlo D; Vendemiale G; Pilotto A; Panza F
Ageing Res Rev; 2010 Oct; 9(4):399-417. PubMed ID: 20444434
[TBL] [Abstract][Full Text] [Related]
3. White matter inflammation and cognitive function in a co-morbid metabolic syndrome and prodromal Alzheimer's disease rat model.
Ivanova N; Liu Q; Agca C; Agca Y; Noble EG; Whitehead SN; Cechetto DF
J Neuroinflammation; 2020 Jan; 17(1):29. PubMed ID: 31964387
[TBL] [Abstract][Full Text] [Related]
4. Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer's disease.
Defrancesco M; Marksteiner J; Deisenhammer E; Kemmler G; Djurdjevic T; Schocke M
J Alzheimers Dis; 2013; 34(3):665-72. PubMed ID: 23254639
[TBL] [Abstract][Full Text] [Related]
5. Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease.
Kandiah N; Chander RJ; Ng A; Wen MC; Cenina AR; Assam PN
Eur J Neurol; 2015 Jan; 22(1):150-5. PubMed ID: 25142829
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging.
Solfrizzi V; Scafato E; Capurso C; D'Introno A; Colacicco AM; Frisardi V; Vendemiale G; Baldereschi M; Crepaldi G; Di Carlo A; Galluzzo L; Gandin C; Inzitari D; Maggi S; Capurso A; Panza F;
Neurobiol Aging; 2011 Nov; 32(11):1932-41. PubMed ID: 20045217
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
8. Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: an interdisciplinary perspective.
Larouche E; Hudon C; Goulet S
Behav Brain Res; 2015 Jan; 276():199-212. PubMed ID: 24893317
[TBL] [Abstract][Full Text] [Related]
9. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
10. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
11. Current epidemiological approaches to the metabolic-cognitive syndrome.
Panza F; Solfrizzi V; Logroscino G; Maggi S; Santamato A; Seripa D; Pilotto A
J Alzheimers Dis; 2012; 30 Suppl 2():S31-75. PubMed ID: 22561330
[TBL] [Abstract][Full Text] [Related]
12. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
[TBL] [Abstract][Full Text] [Related]
13. The Use of Neuroimaging to Assess Associations Among Diet, Nutrients, Metabolic Syndrome, and Alzheimer's Disease.
Pistollato F; Cano SS; Elio I; Vergara MM; Giampieri F; Battino M
J Alzheimers Dis; 2015; 48(2):303-18. PubMed ID: 26401997
[TBL] [Abstract][Full Text] [Related]
14. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
15. Association of metabolic syndrome with Alzheimer disease: a population-based study.
Vanhanen M; Koivisto K; Moilanen L; Helkala EL; Hänninen T; Soininen H; Kervinen K; Kesäniemi YA; Laakso M; Kuusisto J
Neurology; 2006 Sep; 67(5):843-7. PubMed ID: 16966548
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome and amnestic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 findings.
Feng L; Chong MS; Lim WS; Lee TS; Collinson SL; Yap P; Ng TP
J Alzheimers Dis; 2013; 34(3):649-57. PubMed ID: 23246920
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome, hypertension, and nervous system injury: Epidemiological correlates.
Ricci G; Pirillo I; Tomassoni D; Sirignano A; Grappasonni I
Clin Exp Hypertens; 2017; 39(1):8-16. PubMed ID: 28071980
[TBL] [Abstract][Full Text] [Related]
18. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
[TBL] [Abstract][Full Text] [Related]
19. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition.
Tokuchi R; Hishikawa N; Kurata T; Sato K; Kono S; Yamashita T; Deguchi K; Abe K
J Neurol Sci; 2014 Nov; 346(1-2):288-92. PubMed ID: 25248955
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease.
Liu CG; Wang JL; Li L; Wang PC
Int J Mol Med; 2014 Jul; 34(1):160-6. PubMed ID: 24827165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
